Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $1015 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated a Neutral rating on Regeneron Pharmaceuticals, maintaining a price target of $1015.
October 23, 2024 | 4:27 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated a Neutral rating for Regeneron Pharmaceuticals, with a maintained price target of $1015, indicating no expected significant short-term price movement.
The reiteration of a Neutral rating and maintenance of the price target suggests that the analyst does not foresee significant short-term changes in Regeneron's stock price. This indicates stability rather than a bullish or bearish outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100